Led · Series A · Aug 2025

Molecular You uses advanced proteomics and metabolomics to measure over 250 biomarkers from one blood sample, analyzing deep biological pathways to identify root-cause health risks across more than 25 health areas. Its AI-powered platform delivers personalized, actionable lifestyle recommendations for individuals and clinical practices, supporting preventive and precision medicine. The company has launched nationwide in both Canada and the United States through clinical practices and direct-to-consumer online channels. Molecular You partnered with HealthQuest Esoterics to run its current assay as a Lab Developed Test (LDT), making it eligible for reimbursement. The company plans a near-term introduction of a next-generation multi-omic assay that will measure over 800 biomarkers, broadening scope to additional areas including certain cancers. Leadership includes CEO Jim Kean and CMO Dr. Murdoc Khaleghi; the team has demonstrated clinical impact, including the rare, accurate detection of stage 1 pancreatic cancer that enabled early intervention.

Led · Seed · Feb 2025

ONVY develops an AI Health Coach app and enterprise solutions that continuously ingest biometric, behavioral, environmental, and sensor data to deliver instant, personalized health recommendations. The platform integrates with more than 320 wearable devices and analyzes activity, sleep, nutrition, stress markers, and lifestyle habits to provide real-time feedback and long-term behavioral optimization. ONVY is expanding its AI-as-a-Service and Prevention-as-a-Service offerings to support partners in wellness, longevity, and insurance, and plans deeper data integrations and enhanced predictive analytics. The company intends to expand API capabilities to connect with 500+ health data sources and create a broader health intelligence ecosystem. With rising B2B demand, ONVY is positioning its technology for enterprise deployments to improve engagement, retention, and outcomes for corporate partners. The recent financing will accelerate scaling of its platform and commercial expansion from its Munich base.

Led · Convertible Note · Oct 2022

Enterin is a clinical-stage biopharmaceutical company focused on repairing the dysfunctional gut–brain axis in patients with neurodegenerative and metabolic diseases. Its lead compound, ENT-01, displaces membrane-bound α‑synuclein aggregates from enteric nerve cells and seeks to improve neural signaling between the gut and the brain. A second compound, ENT-03, increases insulin sensitivity via central mechanisms and acutely normalized blood sugar in diabetic mice; ENT-03 is being developed for diabetes, obesity, and Alzheimer’s disease. The company announced plans to begin studies in humans in Q1 2023. Financially, Enterin reported $6 million in convertible note funding as an initial tranche of a program of up to $20 million. The financing includes investment from Voloridge Investment Management and David Vogel, who has joined Enterin’s Board of Directors. Enterin develops a novel drug approach aimed at repairing a dysfunctional gut–brain axis in patients with neurodegenerative disease. Its lead compound, ENT-01, displaces membrane-bound alpha-synuclein aggregates from enteric nervous system nerve cells to improve neural signaling between the gut and the brain in preclinical models of Parkinson's disease. The company is progressing ENT-01 through clinical trials focused on reversing constipation in Parkinson's patients and is completing an ongoing Phase 2 study. Enterin plans to use new funds to complete that Phase 2 study, further study the role of alpha-synuclein in PD pathology and begin exploring other indications. Leadership includes Founder, Chairman and CEO Michael Zasloff and Co-Founder, President and Chief Medical Officer Denise Barbut. The company is based in Philadelphia, PA.